Ekrem Türk

@CookCountyIMR has taught me invaluable lessons and constantly challenged me to grow, both as a physician and as a person. I’ve been incredibly lucky to be surrounded by amazing people who pushed me to improve and become the best version of myself. I’ll miss this place deeply, and I’m grateful to close this chapter of my life with a teaching award as a new attending during my chief resident year. #CountyStrong

The chemotherapy-free regimen blinatumomab and ponatinib is associated with significantly improved PFS and OS compared to Hyper-CVAD with ponatinib, with less non-relapse morality and a reduced reliance on allo-SCT in Ph+ ALL. doi.org/10.1002/ajh.70… @AjHematology @UTMDAnderson

💉 Romiplostim (TPO-RA) – dosing & side effects (ITP adults) 🧪 Starting dose → 1 mcg/kg SC weekly 📈 Titrate weekly based on platelet count: ➡️ ↑ by +1 mcg/kg/week if PLT <50 ×10⁹/L ➡️ Maintain if PLT 50–200 ×10⁹/L 🎯 ➡️ ↓ dose if PLT >200 ➡️ Hold if PLT >400 → restart lower dose 📊 Max dose → 10 mcg/kg/week ⏱️ Time to response → ~1–2 weeks (peak effect ~2–3 weeks) 🎯 Goal → keep PLT ≥50 (NOT normalization) ⚠️ Key side effects: 🩸 Thrombosis risk ↑ (especially if PLT overshoot) 🧬 Bone marrow reticulin fibrosis (reversible usually) 🔄 Rebound thrombocytopenia after stopping 🤕 Headache (common) 🦴 Arthralgia / myalgia 📈 Mild ↑ LFTs (rare) ⚠️ Rare → progression of MDS to AML if misused 🔬 Monitoring: 📊 Weekly platelets until stable → then monthly 🧫 Periodic smear ± marrow if atypical 📌 Pearl: ❗ Do NOT chase normal platelets → ↑ thrombosis risk #ITP #Romiplostim #Hematology #Platelets #MedEd

Νοvel Therapies in High‐Risk Myelodysplastic Syndromes - Galanopoulos - European Journal of Haematology - Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/ej… #mds

AML Therapeutic Timeline🧬 •1970–2000s: 7+3backbone ± •2017 :Targeted era begins  –FLT3(midostaurin, gilteritinib, quizartinib)  –IDH1/2(ivosidenib, enasidenib)  –CPX-351 for AML-MR  –Venetoclax + HMA/LDAC for unfit/older • 2024–2025: Menin inhibitors (revumenib, ziftomenib)

Targeted therapies in AML. So many! FLT3 mutation = gilteritinib, midostaurin, quizartinib IDH1 mutation = ivosidenib, olutasidenib IDH2 mutation = enasidenib KMT2A rearrangement = revumenib NPM1 mutatuion = revumenib, ziftomenib CD33 = gemtuzumab ozogamicin BCL2 = venetoclax

Amazing mentor! Definitely one of the highlights of my training @MoffittNews

Thank U, Dr @PatrickHwuMD! It’s a privilege to work under your leadership w/ the incredible colleagues @MoffittNews. Honored to share our vision w/patients & have their trust!🩷 The bar is now officially set high for me after this shout-out! 📈😊

ASH has released new guidelines for frontline management of ALL in adolescents and young adults. The recommendations focus on pediatric-inspired regimens, asparaginase use, and transplant decisions in first remission. Learn more: bit.ly/4aPFtb5 #Hematology #HemeOnc

Maintenance therapy after alloHCT in high-risk #AML has long been a grey area. This study provides a strong scientific rationale for post-alloHCT maintenance with menin inhibitors, enhancing GVL. #menin_inhibitors @BloodPortfolio #weekend_review doi.org/10.1182/blood.…

Diagnosis & Management of Advanced Phase / Blast-Phase CML #CML #weekend_review #leusm

@forzacimbom Tek gerçek kral @hakansukur u yazmayı unutma!!!! 👑 🦁

🩸𝟯𝟬𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗼𝗻 𝗛𝗲𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝗶𝗰 𝗠𝗮𝗹𝗶𝗴𝗻𝗮𝗻𝗰𝗶𝗲𝘀®: 𝗙𝗼𝗰𝘂𝘀 𝗼𝗻 𝗟𝗲𝘂𝗸𝗲𝗺𝗶𝗮𝘀, 𝗟𝘆𝗺𝗽𝗵𝗼𝗺𝗮𝘀, 𝗮𝗻𝗱 𝗠𝘆𝗲𝗹𝗼𝗺𝗮 🗓️𝘍𝘦𝘣𝘳𝘶𝘢𝘳𝘺 26-28, 2026 𝗙𝗥𝗘𝗘 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗵𝗲𝗻 𝘆𝗼𝘂 𝘂𝘀𝗲 𝗰𝗼𝗱𝗲 𝗜𝗔𝗖𝗛 *𝘛𝘩𝘦 𝘥𝘪𝘴𝘤𝘰𝘶𝘯𝘵 𝘪𝘴 𝘢𝘱𝘱𝘭𝘪𝘤𝘢𝘣𝘭𝘦 𝘦𝘹𝘤𝘭𝘶𝘴𝘪𝘷𝘦𝘭𝘺 𝘵𝘰 𝘩𝘦𝘢𝘭𝘵𝘩 𝘤𝘢𝘳𝘦 𝘱𝘳𝘰𝘧𝘦𝘴𝘴𝘪𝘰𝘯𝘢𝘭𝘴. 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗯𝗲𝗹𝗼𝘄⤵️ gotoper.com/courses/intern… 𝗕𝗲 𝘀𝘂𝗿𝗲 𝘁𝗼 𝗮𝘁𝘁𝗲𝗻𝗱 𝘁𝗵𝗲 𝟯𝟬𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗼𝗻 𝗛𝗲𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝗶𝗰 𝗠𝗮𝗹𝗶𝗴𝗻𝗮𝗻𝗰𝗶𝗲𝘀®: 𝘍𝘰𝘤𝘶𝘴 𝘰𝘯 𝘓𝘦𝘶𝘬𝘦𝘮𝘪𝘢𝘴, 𝘓𝘺𝘮𝘱𝘩𝘰𝘮𝘢𝘴, 𝘢𝘯𝘥 𝘔𝘺𝘦𝘭𝘰𝘮𝘢, 𝘸𝘩𝘪𝘤𝘩 𝘸𝘪𝘭𝘭 𝘮𝘢𝘬𝘦 𝘢 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘤𝘦 𝘪𝘯 𝘪𝘮𝘱𝘳𝘰𝘷𝘪𝘯𝘨 𝘤𝘢𝘳𝘦 𝘧𝘰𝘳 𝘺𝘰𝘶𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴. 𝘛𝘩𝘪𝘴 𝘦𝘯𝘨𝘢𝘨𝘪𝘯𝘨 𝘢𝘯𝘥 𝘩𝘪𝘨𝘩𝘭𝘺 𝘪𝘯𝘵𝘦𝘳𝘢𝘤𝘵𝘪𝘷𝘦 𝘮𝘦𝘦𝘵𝘪𝘯𝘨 𝘸𝘪𝘭𝘭 𝘱𝘳𝘰𝘷𝘪𝘥𝘦 𝘢𝘮𝘱𝘭𝘦 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘺 𝘧𝘰𝘳 𝘺𝘰𝘶 𝘵𝘰 𝘪𝘯𝘵𝘦𝘳𝘢𝘤𝘵 𝘸𝘪𝘵𝘩 𝘪𝘯𝘵𝘦𝘳𝘯𝘢𝘵𝘪𝘰𝘯𝘢𝘭𝘭𝘺 𝘳𝘦𝘯𝘰𝘸𝘯𝘦𝘥 𝘦𝘹𝘱𝘦𝘳𝘵𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘮𝘢𝘯𝘢𝘨𝘦𝘮𝘦𝘯𝘵 𝘰𝘧 𝘭𝘦𝘶𝘬𝘦𝘮𝘪𝘢𝘴, 𝘭𝘺𝘮𝘱𝘩𝘰𝘮𝘢𝘴, 𝘮𝘺𝘦𝘭𝘰𝘮𝘢, 𝘮𝘺𝘦𝘭𝘰𝘥𝘺𝘴𝘱𝘭𝘢𝘴𝘵𝘪𝘤 𝘴𝘺𝘯𝘥𝘳𝘰𝘮𝘦𝘴, 𝘢𝘯𝘥 𝘮𝘺𝘦𝘭𝘰𝘱𝘳𝘰𝘭𝘪𝘧𝘦𝘳𝘢𝘵𝘪𝘷𝘦 𝘯𝘦𝘰𝘱𝘭𝘢𝘴𝘮𝘴. @Mohty_EBMT @mvmateos @Daver_Leukemia @AjaiChari

📣Tomorrow! Jan 16th, 3pm EST Join Dr. Hal Burstein (@DrHBurstein) to learn the latest updates on treatment and research breakthroughs for #MetastaticBreastCancer from the 2025 San Antonio Breast Cancer Symposium. #SABCS25 dfci.zoom.us/webinar/regist…

Today I learned that chewing cardamom twice a day or smelling lemon/cloves twice a day might help with the dysgeusia associated with tarlatamab (the CD3-DLL3 bispecific T cell engaged used to treat SCLC)!

CML recommendations ELN&NCCN 2025 #ASH25

ASH 2025 Insights: The MEASURE Genome Atlas - AML at Diagnosis and Complete Remission | Vumedi vumedi.com/video/ash-2025…

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party ashpublications.org/blood/article/…

@ZhuoerXie @MoffittNews ♥️

⁦@TheIACH⁩ Post #ASH25 Myeloma Roundtable is coming on December 15! Join a world-class faculty as we digest everything you need to know about the breakthrough myeloma data presented: sharp insights, honest debates, and practice-changing takeaways. us06web.zoom.us/webinar/regist…

@Mohty_EBMT are you planning to do #ASH2025 dedicated post congress webinar? I am a huge fan of #IACH contents as a new fellow. A great learning opportunity, coming directly from experts in the field, is priceless.